Sellas Life Sciences Group Inc (SLS)
EBITDA Growth
-45.51%
Quarterly · Period ending:
SLS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-45.51%period ending
Latest reported-45.51%period ending
SLS Quarterly EBITDA YoY % (-255.61% → -45.51%)
Year-over-year change
High-resolution chart · PNG
SLS ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -45.5083% | |
| -44.6241% | |
| -13.6708% | |
| 104.108% | |
| 11.6332% | |
| 39.2327% | |
| 17.1952% | |
| 23.2977% | |
| 13.9599% | |
| 13.7965% | |
| 9.5799% | |
| -35.9795% | |
| -4.2007% | |
| 33.5469% | |
| -61.7763% | |
| 3.8109% | |
| -80.62% | |
| -1,093.6382% | |
| -36.2567% | |
| -57.7248% | |
| -8.1087% | |
| 65.5758% | |
| -9.9902% | |
| -8.8798% | |
| 4.5785% | |
| -100% | |
| -33.4205% | |
| 32.162% | |
| -92.2799% | |
| 135.0261% | |
| 31.3985% | |
| -1.9231% | |
| 50.4585% | |
| 6.1668% | |
| 24.0381% | |
| 38.6115% | |
| 49.7358% | |
| 5.3462% | |
| 30.9915% | |
| -2.5889% | |
| -0.919% | |
| 32.4431% | |
| 17.8616% | |
| 42.1371% | |
| 24.1284% | |
| 7.5253% | |
| -53.1629% | |
| -95.7217% | |
| -75.7755% | |
| 35.5483% | |
| -22.4615% | |
| -39.8873% | |
| -51.3049% | |
| -224.2855% | |
| -62.8352% | |
| -154.6392% | |
| 16.6094% | |
| -58.1211% | |
| 7.7237% | |
| 52.6428% | |
| -18.6679% | |
| 30.4306% | |
| 6.6751% | |
| 6.3978% | |
| -6.7989% | |
| -31.4629% | |
| -14.7684% | |
| -16.6937% | |
| -53.9866% | |
| -46.5492% | |
| -19.0361% | |
| 11.7274% | |
| -90.8962% | |
| -255.6136% |